REPOSITORY CORTICOTROPIN INJECTION (H.P. ACTHAR GEL®)

Policy Number: PHARMACY 214.14 T2

Table of Contents

- INSTRUCTIONS FOR USE .......................................................... 1
- CONDITIONS OF COVERAGE .................................................. 1
- BENEFIT CONSIDERATIONS ..................................................... 2
- COVERAGE RATIONALE .......................................................... 2
- U.S. FOOD AND DRUG ADMINISTRATION ..................................... 3
- BACKGROUND ............................................................................... 3
- APPLICABLE CODES ............................................................... 3
- CLINICAL EVIDENCE ............................................................... 3
- REFERENCES ............................................................................... 6
- POLICY HISTORY/REVISION INFORMATION .............................. 7

Related Policies

- Acquired Rare Disease Drug Therapy Exception Process
- Drug Coverage Guidelines
- Experimental/Investigational Treatment
- Experimental/Investigational Treatment for NJ Plans

INSTRUCTIONS FOR USE

This Clinical Policy provides assistance in interpreting Oxford benefit plans. Unless otherwise stated, Oxford policies do not apply to Medicare Advantage members. Oxford reserves the right, in its sole discretion, to modify its policies as necessary. This Clinical Policy is provided for informational purposes. It does not constitute medical advice. The term Oxford includes Oxford Health Plans, LLC and all of its subsidiaries as appropriate for these policies.

When deciding coverage, the member specific benefit plan document must be referenced. The terms of the member specific benefit plan document [e.g., Certificate of Coverage (COC), Schedule of Benefits (SOB), and/or Summary Plan Description (SPD)] may differ greatly from the standard benefit plan upon which this Clinical Policy is based. In the event of a conflict, the member specific benefit plan document supersedes this Clinical Policy. All reviewers must first identify member eligibility, any federal or state regulatory requirements, and the member specific benefit plan coverage prior to use of this Clinical Policy. Other Policies may apply.

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The MCG™ Care Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

CONDITIONS OF COVERAGE

<table>
<thead>
<tr>
<th>Applicable Lines of Business/ Products</th>
<th>Referral Required (Does not apply to non-gatekeeper products)</th>
<th>Authorization Required (Precertification always required for inpatient admission)</th>
<th>Precertification with Medical Director Review Required</th>
<th>Applicable Site(s) of Service (If site of service is not listed, Medical Director review is required)</th>
<th>Special Considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>This policy applies to Oxford Commercial plan membership.</td>
<td>Medical²</td>
<td>No</td>
<td>Yes¹,²,³</td>
<td>Yes²</td>
<td>Other</td>
</tr>
</tbody>
</table>

¹Providers must call Oxford’s Pharmacy Benefit Manager (PBM) to obtain precertification for self-administration, covered under the pharmacy benefit. Refer to: Drug Coverage Guidelines.

²Precertification through Oxford’s Medical Management...
Special Considerations (continued)

BENEFIT CONSIDERATIONS

Before using this policy, please check the member specific benefit plan document and any federal or state mandates, if applicable.

- Some states mandate benefit coverage for off-label use of medications for some diagnoses or under some circumstances when certain conditions are met. Where such mandates apply, they supersede language in the benefit document or in the medical or drug policy.
- Not all Oxford Members have pharmacy coverage. Refer to the member specific benefit plan document for additional information.
- For information regarding self-administration of H.P. Acthar Gel, refer to the policy titled Drug Coverage Guidelines.
- For information regarding applicable quantity level limitations, refer to the policy titled Drug Coverage Guidelines.
- Some Certificates of Coverage allow for coverage of experimental/investigational treatments for life-threatening illnesses when certain conditions are met. The member specific benefit plan document must be consulted to make coverage decisions for this service. Refer to the policies titled Experimental/Investigational Treatment and Experimental/Investigational Treatment for NJ Plans.
- Benefit coverage for an otherwise not medically necessary service for the treatment of serious rare diseases may occur when certain conditions are met. Refer to the policy titled Acquired Rare Disease Drug Therapy Exception Process.

Essential Health Benefits for Individual and Small Group

For plan years beginning on or after January 1, 2014, the Affordable Care Act of 2010 (ACA) requires fully insured non-grandfathered individual and small group plans (inside and outside of Exchanges) to provide coverage for ten categories of Essential Health Benefits ("EHBs"). Large group plans (both self-funded and fully insured), and small group ASO plans, are not subject to the requirement to offer coverage for EHBs. However, if such plans choose to provide coverage for benefits which are deemed EHBs, the ACA requires all dollar limits on those benefits to be removed on all Grandfathered and Non-Grandfathered plans. The determination of which benefits constitute EHBs is made on a state by state basis. As such, when using this policy, it is important to refer to the member specific benefit plan document to determine benefit coverage.

COVERAGE RATIONALE

H.P. Acthar Gel (repository corticotropin injection is proven and medically necessary for the treatment of:

- Infantile spasm (i.e., West Syndrome)\(^1\) for up to 4 weeks when all of the following criteria are met:
  - Diagnosis of infantile spasms (i.e., West Syndrome)\(^1\); and
  - Patient is less than 2 years old; and
  - H.P Acthar Gel dosing for infantile spasm is as follows:
    - Initial dose: 75 U/m\(^2\) intramuscular (IM) twice daily for 2 weeks
    - After 2 weeks, dose should be tapered according to the following schedule: 30 U/m\(^2\) IM in the morning for 3 days; 15 U/m\(^2\) IM in the morning for 3 days; 10 U/m\(^2\) IM in the morning for 3 days; and 10 U/m\(^2\) IM every other morning for 6 days (3 doses)

- Opsoclonus-myoclonus syndrome (i.e., OMS, Kinsbourne Syndrome)\(^1\)

H.P Acthar Gel is not medically necessary for treatment of acute exacerbations of multiple sclerosis.

Published clinical evidence does not demonstrate superiority of Acthar to other available corticosteroids.

Although FDA labeling suggests that H.P. Acthar may be used in the following conditions, it is not FDA indicated.

H.P. Acthar Gel is unproven and not medically necessary for treatment of the following disorders and diseases:

- Rheumatic disorders: psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis, ankylosing spondylitis
- Collagen diseases: systemic lupus erythematosus, systemic dermatomyositis (polymyositis)
- Dermatologic diseases: severe erythema multiforme, Stevens-Johnson syndrome
- Allergic states: serum sickness
- Ophthalmic diseases: severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation
- Respiratory diseases: symptomatic sarcoidosis
- Edematous state: to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus
- Any indication outside of the medically necessary indications above

U.S. FOOD AND DRUG ADMINISTRATION (FDA)

H.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue indicated as monotherapy for the treatment of infantile spasms in infants and children less than 2 years of age and for the treatment of exacerbations of multiple sclerosis in adults. H.P. Acthar Gel may be used for the following disorders and diseases: rheumatic; collagen; dermatologic; allergic states; ophthalmic; respiratory; and edematous state.\(^1\)

BACKGROUND

Repository corticotropin injection (H.P. Acthar Gel\(^\circledR\)) is an adrenocorticotropic hormone (ACTH) analogue.\(^1-3\) Repository corticotropin injection and ACTH stimulate the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances. Prolonged administration of large doses of repository corticotropin injection induces hyperplasia and hypertrophy of the adrenal cortex and continuous high output of cortisol, corticosterone and weak androgens. The release of endogenous ACTH is influenced by the nervous system via the regulatory hormone released from the hypothalamus and by a negative corticosteroid feedback mechanism. Elevated plasma cortisol suppresses ACTH release. Repository corticotropin injection also binds to melanocortin receptor. Both endogenous ACTH and repository corticotropin injection have a trophic effect on the adrenal cortex which is mediated by cyclic adenosine monophosphate (cyclic AMP).

APPLICABLE CODES

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies may apply.

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0800</td>
<td>Injection, corticotropin, up to 40 units</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10 Diagnosis Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>G25.3</td>
<td>Myoclonus</td>
</tr>
<tr>
<td>G25.9</td>
<td>Extrapyramidal and movement disorder, unspecified</td>
</tr>
<tr>
<td>G40.821</td>
<td>Epileptic spasms, not intractable, with status epilepticus</td>
</tr>
<tr>
<td>G40.822</td>
<td>Epileptic spasms, not intractable, without status epilepticus</td>
</tr>
<tr>
<td>G40.823</td>
<td>Epileptic spasms, intractable, with status epilepticus</td>
</tr>
<tr>
<td>G40.824</td>
<td>Epileptic spasms, intractable, without status epilepticus</td>
</tr>
<tr>
<td>H55.89</td>
<td>Other irregular eye movements</td>
</tr>
</tbody>
</table>

CLINICAL EVIDENCE

Proven/Medically Necessary

Infantile Spasms (i.e., West Syndrome)

In a single-center, single-blind, parallel-group, randomized clinical trial, Wanigasinghe et al, investigated whether ACTH is not superior to high-dose prednisolone for treatment of newly diagnosed West Syndrome (WS). Ninety-seven infants, newly diagnosed with WS, were randomized to receive either 14 days of oral prednisolone (40 to 60 mg/day) or an intramuscular (IM) injection of ACTH (40 to 60 IU/ every other day). This followed the United Kingdom Infantile Spasm Study protocol. Infantile spasm (IS) remission was blindly evaluated by day 14, including using a 30 minute electroencephalograph (EEG) as well as continued spasm freedom for 28 days. Forty-eight infants received prednisolone and 49 infants received ACTH. By day 14, 58.3% of infants (28/48) on prednisolone compared with only 36.7% (18/49) of infants given ACTH (P=0.03). EEG and spasm cessation showed electroclinical remission in 21 prednisolone infants versus 9 ACTH infants (P = 0.008). Days required for spasm remission was significantly less in
the prednisolone group (3.85 days ± 2.4) compared with ACTH (8.65 days ± 3.7) (P = 0.001). The authors concluded that ACTH therapy at the trial dose did not yield superior rates of EEG or clinical remission when compared with the trial dose of prednisolone. More patients achieved electroclinical remission when treated with prednisolone than with ACTH.

**Opsoclonus-Myoclonus Syndrome (OMS, Kinsbourne Syndrome)**

Tate et al evaluated the efficacy and safety of corticotropin-based immunotherapies in a prospective, rater-blinded, exploratory study of previously untreated or steroid-dependent children (n=74) with opsonolus-myoclonus syndrome (OMS). Children with neuroblastomas were excluded. Children were put into 1 of 6 groups: corticotropin alone or with intravenous immunoglobulin (groups 1 and 2, active controls); or both with rituximab (group 3) or cyclophosphamide (group 4); or with rituximab plus chemotherapy (group 5) or steroid sparsers (group 6). Data was obtained through the Corticotropin Intake Form and Opsonolus-Myoclonus Evaluation Scale. The primary end points were reduction in clinical severity relative to baseline (posttreatment total score and percentage improvement in total score). Researchers found that there was a 65% improvement in motor severity score across groups (p<0.0001), but treatment combinations were more effective than corticotropin monotherapy (p=0.0009). Groups 3, 4, and 5 responded better than group 1; groups 3 and 5 responded better than group 2. The response frequency to corticotropin was higher than to prior corticosteroids (p<0.0001). Adverse events (corticosteroid excess) were reported in 55% of children, more so with multiagents (p=0.03); and 10% of children (n=7) had serious adverse events which were heterogeneous in etiology. Researchers concluded that the study demonstrated the greater efficacy of corticotropin-based multimodal therapy compared with conventional therapy and a greater response to corticotropin than corticosteroid-based therapy.

Cerebrospinal fluid (CSF) adrenocorticotropic hormone (ACTH) concentration and cortisol were measured in 69 children with opsonolus-myoclonus syndrome (OMS) and 25 age- and sex matched control subjects to determine endogenous levels and to look for hypothesized differential hormonal effects of ACTH and corticosteroid treatment. To compare high-dose versus low-dose, the ACTH-treated group was divided at the median (32 IU/m²/day) and the steroid group was also divided at the median (1.5 mg/kg/day). In cases of alternate day dosing, the dose was halved as an approximation for comparison with the daily dose group. CSF cortisol was 10-fold higher in the 26 patients receiving ACTH treatment (p<0.05), but was unchanged with oral steroid treatment (n = 18) or no treatment (n = 25). It was significantly higher (25-fold) in children receiving daily high-dose ACTH than alternate day ACTH. In ACTH-treated children, CSF and serum cortisol were highly correlated (p=0.0001), with a mean ratio of CSF to serum cortisol of approximately 1:10. CSF ACTH concentration did not differ significantly between untreated OMS and control subjects but was lower with ACTH (-29%) or steroid treatment (-36%), suggesting feedback inhibition of ACTH release (p<0.05). Results indicated that daily high-dose ACTH treatment dramatically raises the concentration of CSF cortisol, but alternate day and low-dose ACTH did not. Researchers conclude that to the extent that cortisol is a factor in clinical response to ACTH therapy, data supports the use of high-dose ACTH protocols in OMS. Additionally, elevated brain cortisol may contribute to the superiority of ACTH treatment over oral corticosteroids in inducing a neurologic remission in OMS.

**Unproven/Not Medically Necessary**

H.P. Acthar has additional uses listed in the FDA-label: Since H.P. Acthar is more costly than an alternative drug that is at least as likely to produce equivalent therapeutic results, UHCP has determined that use of H.P. Acthar Gel is unproven and not medically necessary for treatment of the following disorders and diseases:

- **Rheumatic disorders**: psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis, ankylosing spondylitis
- **Collagen diseases**: systemic lupus erythematosus, systemic dermatomyositis (polymyositis)
- **Dermatologic diseases**: severe erythema multiforme, Stevens-Johnson syndrome
- **Allergic states**: serum sickness
- **Ophthalmic diseases**: severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation
- **Respiratory diseases**: symptomatic sarcoidosis
- **Edematous state**: to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus

**Technology Assessments**

In October 2014, The National Institute for Health and Care Excellences (NICE) published an updated clinical guideline entitled Management of Multiple Sclerosis (MS) in Primary and Secondary Care (Clinical Guideline 186). In this publication, the Guideline Development Group (GDG) noted that some evidence for steroid use comes from older trials that had used ACTH but that ACTH is no longer used as a treatment option for acute relapse of MS. The GDG considered that steroids are the common accepted treatment for relapse and that delivery is dependent on service organization.
In 2013, an update to the 2000 Cochrane review was published evaluating efficacy and safety of corticosteroids or adrenocorticotropic hormone (ACTH) in reducing short and long term morbidity associated with multiple sclerosis (MS). Authors conclude that:

- The trials evaluated showed that corticosteroids (methylprednisolone (MP)) or ACTH favored recovery from acute exacerbation in MS, which increased the probability of ameliorating the episode within the first five weeks of treatment by more than 60%. Evidence found that corticosteroids, notably MP, are effective in the treatment of acute exacerbation, increasing the probability of ameliorating the episode and speeding up patient recovery.
- There was insufficient evidence to determine if steroids or ACTH treatment prevented new exacerbations and worsening of long term disability in MS.
- Evidence on the efficacy of different types or schedules of therapies was limited. Indirect comparisons suggest a significantly greater effect of MP versus ACTH.

In 2013, a Cochrane review was published comparing the effects of single drugs used to treat infantile spasms in terms of long-term psychomotor development, spasm control, subsequent epilepsy, and adverse effects. Authors concluded that:

- To date, few well-designed randomized controlled trials have considered the treatment of infantile spasms, and the numbers of patients enrolled have been small.
- In the majority, methodology has been poor, hence it is not clear which treatment is optimal in the treatment of this epilepsy syndrome.
- Hormonal treatment resolves spasms in more infants than vigabatrin, but this may or may not translate into better long-term outcomes.
- If prednisolone or vigabatrin is used, high dosage is recommended.
- Vigabatrin may be the treatment of choice in tuberous sclerosis.
- Resolution of the EEG features may be important, but this has not been proven.
- Further research using large studies with robust methodology is required.

In 2010, the Infantile Spasms Working Group (ISWG) developed a consensus of the U.S. approach to the diagnostic evaluation and treatment of infantile spasms. There was strong consensus on the following four conclusions:

- The need for broad clinical evaluation, including detailed clinical neurophysiology was strongly recommended.
- ACTH and vigabatrin are the only drugs with proven effectiveness to suppress clinical spasms and abolish the hypsarrhythmic EEG (a specific EEG pattern found only in this syndrome) in a randomized clinical trial setting and thus remain first line treatments.
- Regardless of the chosen medication, timely assessment of treatment efficacy, i.e., two weeks for ACTH followed by taper (two weeks or less following dose titration for vigabatrin) and, if indicated, prompt treatment modification is strongly recommended as longer treatment trials, i.e., greater than two weeks for ACTH; greater than three months for vigabatrin are not likely to be effective and may come at the expense of serious adverse events.
- Effective treatment for infantile spasms should produce both cessation of spasms and resolution of hypsarrhythmia on EEG and is an all or none “response.”

Professional Societies

In the 2012, the American Academy of Neurology (AAN) updated their 2004 evidence-based guideline which summarizes the most effective therapies for infantile spasms, their safety, and whether successful treatment of infantile spasms leads to long-term improvement. The recommendations of the AAN and Child Neurology Society (CNS) regarding medical treatment of infantile spasms in children is as follows for adrenocorticotropic hormone (ACTH)*:

- The evidence is insufficient to recommend the use of prednisolone, dexamethasone, and methylprednisolone as being as effective as ACTH for short-term treatment of infantile spasms (Level U).
- Low-dose ACTH should be considered as an alternative to high-dose ACTH for treatment of infantile spasms (Level B).
- ACTH (Level B) or VGB (Level C) may be offered for short-term treatment of infantile spasms. Evidence suggests that ACTH may be offered over VGB (Level C).
- Hormonal therapy (ACTH or prednisolone) may be considered for use in preference to VGB in infants with cryptogenic infantile spasms, to possibly improve developmental outcome (Level C).
- A shorter lag time to treatment of infantile spasms with either hormonal therapy or VGB may be considered to improve long-term cognitive outcomes (Level C).

*AAN Rating of Recommendation:

- Level A: Established as effective, ineffective or harmful for the given condition in the specified population
- Level B: Probably effective, ineffective, or harmful (or probably useful/predictive or not useful/predictive) for the given condition in the specified population
- Level C: Possibly effective, ineffective, or harmful (or possibly useful/predictive or not useful/predictive) for the given condition in the specified population
The foregoing Oxford policy has been adapted from an existing UnitedHealthcare Pharmacy Clinical Pharmacy Program that was researched, developed and approved by the UnitedHealth Group National Pharmacy & Therapeutics Committee [2016D0037G]


POLICY HISTORY/REVISION INFORMATION

<table>
<thead>
<tr>
<th>Date</th>
<th>Action/Description</th>
</tr>
</thead>
</table>
| 02/01/2017 | • Removed language pertaining to New Jersey (NJ) Individual Plans *(NJ individual benefit plans transitioned to UnitedHealthcare Oxford Navigate effective Jan. 1, 2017)*  
• Revised conditions of coverage/precertification requirements to indicate precertification with medical director review is required  
• Updated benefit considerations:  
  o Added language to indicate the member specific benefit plan document must be consulted to make coverage decisions for experimental/investigational treatments for life-threatening illnesses when certain conditions are met  
  o Replaced language indicating:  
    ▪ “Some states mandate benefit coverage for off-label use of medications for some diagnoses or under some circumstances” with “some states mandate benefit coverage for off-label use of medications for some diagnoses or under some circumstances when certain conditions are met”  
    ▪ “Some states also mandate usage of other Compendium references; where such mandates apply, they supersede language in the benefit document or in the coverage criteria” with “where such mandates apply, they supersede language in the benefit document or in the medical or drug policy”  
• Updated coverage guidelines:  
  o Removed statement describing services addressed in the policy  
  o Added language to clarify although FDA labeling suggests that H.P. Acthar may be used for the listed unproven/not medically necessary indications, it is not FDA indicated for these disorders and diseases  
• Updated supporting information to reflect the most current references  
• Archived previous policy version PHARMACY 214.13 T2 |